Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Shasun Pharmaceuticals Ltd

    Shasun is an integrated, global supplier of development and manufacturing services for intermediates, API (Active Pharmaceutical Ingredients) and Formulations to the Pharmaceuti

  • No Image
    Shayona Enterprise Pvt Ltd

    Shayona Enterprise Private Limited is a manufacturer, supplier and exporter of chemical products. Industrial chemicals that they have introduced are feed grade additive, anhydro

  • No Image
    Shilpa Medicare Ltd

    Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in Novem

  • No Image
    Shreegen Pharma Ltd

    ShreeGen Pharma Limited is a closely held public limited company engaged in the manufacturing of Active Pharmaceutical ingredients and bulk drugs. The Company had commenced its